Vertex Pharmaceuticals (VRTX) initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting kidney function. This phase III portion will evaluate a 45 mg oral dose of Vertex’s drug, on top of standard of care, in AMKD patients, compared with placebo. Management also expanded the study to include adolescents aged 10 and older with AMKD. Previously, the AMPLITUDE study only enrolled adults with the disea ...